-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMU-856 in Celiac Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.IMU-856 in Celiac DiseaseDrug Details:IMU-856 is under development for the treatment of Crohn's disease, irritable bowel...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – M-4076 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. M-4076 in Solid Tumor Drug Details: M-4076 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TO-O-1001 in Ocular Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TO-O-1001 in Ocular HypertensionDrug Details:TO-O-1001 is under development for the treatment of open-angle glaucoma and ocular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AUT-00206 in Fragile X Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AUT-00206 in Fragile X SyndromeDrug Details:AUT-00206 is under development for the treatment of fragile X syndrome....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-385 in Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CKD-385 in Hypertension Drug Details: CKD-385 is under development for the treatment of hyperlipidemia, hypertension,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – It-hMSC in Dementia Associated With Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. It-hMSC in Dementia Associated With Alzheimer's Disease Drug Details: Stem cell therapy (Stemedyne-MSC) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Oligonucleotides To Inhibit Kras For Pancreatic Ductal Adenocarcinoma in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Oligonucleotides To Inhibit Kras For Pancreatic Ductal Adenocarcinoma in Pancreatic Ductal AdenocarcinomaDrug Details:Oligonucleotides are under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Social Anxiety Disorder (SAD/Social Phobia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Social Anxiety Disorder (SAD/Social Phobia) Drug Details: Cannabidiol is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CDK-002 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CDK-002 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: CDK-002Â is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CDK-002 in Cutaneous Squamous Cell Carcinoma (cSCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CDK-002 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug Details: CDK-002Â is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.